Brought to you by 
Series C lands $100mm for Innovent Biologics
22 Jan 2015
Executive Summary
Chinese biopharma Innovent Biologics Inc. raised $100mm in its Series C financing led by Legend Capital, which was joined by other first-time backers Temasek and two undisclosed investors, and returning shareholders Fidelity Biosciences, Fidelity Growth Partners Asia, Lilly Asia Ventures, and Frontline Bioventures. Proceeds will help fund its antibody pipeline, consisting of one candidate with an approved IND and four which have been filed for approval. Therapy areas for Innovent’s compounds include cancer, autoimmune disease, and diabetes.
Deal Industry
- Pharmaceuticals
- Services
-
Biotechnology
- Synthesis Technologies, Production Processes
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Series C lands $100mm for Innovent Biologics
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice